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ABSTRACT 
 
Neonatal diabetes and hypothyroidism (NDH) syndrome was first described in 2003 in a 
consanguineous Saudi Arabian family where two out of four siblings were reported to have 
presented with proportionate IUGR, neonatal non-autoimmune diabetes mellitus, severe 
congenital hypothyroidism, cholestasis, congenital glaucoma, and polycystic kidneys. Liver 
disease progressed to hepatic fibrosis. The renal disease was characterised by enlarged 
kidneys and multiple small cysts with deficient cortico-medullary junction differentiation and 
normal kidney function. There was minor facial dysmorphism (depressed nasal bridge, large 
anterior fontanelle, long philtrum) reported but no facial photographs were published.  
Mutations in the transcription factor GLI-similar 3 (GLIS3) gene in the original family and two 
other families were subsequently reported in 2006. All affected individuals had neonatal 
diabetes, congenital hypothyroidism but glaucoma and liver and kidney involvement were less 
consistent features. Detailed descriptions of the facial dysmorphism have not been reported 
previously. In this report, we describe the common facial dysmorphism consisting of bilateral 
low-set ears, depressed nasal bridge with overhanging columella, elongated, upslanted 
palpebral fissures, persistent long philtrum with a thin vermilion border of the upper lip in a 
cohort of seven patients with GLIS3 mutations and report the emergence of a distinct, 
probably recognisable facial gestalt in this group which evolves with age. 
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INTRODUCTION 
 
Taha et al., in 2003 described the first consanguineous Saudi Arabian family in which 
2 of 4 siblings had permanent neonatal diabetes associated with intrauterine growth 
retardation (IUGR), congenital hypothyroidism, facial anomalies, congenital glaucoma, 
hepatic fibrosis, and polycystic kidneys, described as NDH (Neonatal Diabetes and 
Hypothyroidism) syndrome [Taha et al., 2003]. Genome wide linkage analysis and 
sequencing of candidate genes performed on this family by Senee et al., in 2006 identified a 
homozygous frameshift mutation (c.1873dupC, previously reported as 2067insC) in GLIS3 
which is likely to result in transcript degradation by nonsense mediated decay (NMD). Both 
children with this mutation died in infancy. A child born subsequently in this family died of the 
same condition prior to confirmatory genetic testing [Habeb et al., 2012]. Senee et al., 2006 
described two further families with mutations in GLIS3. The first harboured a homozygous 
426-kb deletion, which encompassed the SLC1A1 gene and part of GLIS3. The affected 
offspring in the second family carried a homozygous 149-kb deletion that included a portion of 
GLIS3 as well; the region common to both deletions mapped to the known start codon of 
GLIS3. Patients in both these families presented with a milder phenotype with the absence of 
renal or liver disease. Additional features in these and subsequent patients described include 
intrauterine growth retardation (IUGR), developmental delay and congenital glaucoma [Senee 
et al., 2006]. We recently published a large series of 12 patients worldwide with mutations in 
GLIS3 thus expanding the clinical spectrum of abnormalities resulting from disruption of Glis3 
function. These include exocrine pancreatic insufficiency, osteopenia, fractures with delayed 
fracture healing, craniosynostosis, hiatus hernia, congenital cardiac disease, splenic and 
pancreatic cysts and choanal atresia [Dimitri et al., 2015].  
 
A facial phenotype has been cited in patients with mutations in GLIS3 [Taha et al., 
2003; Senee et al., 2006]. Facial dysmorphology previously described includes a large and 
squared shape of the face, with a thin curved nose and previous reports suggest that the 
facial features attenuate with growth. To date, the facial phenotype in patients with GLIS3 
mutations has not been described in detail and the degree of consistency in these features 
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between patients has not been reported. We thus reviewed the features in 7 patients with 
GLIS3 mutations in whom written consent was obtained for publication of images to 
determine whether a consistent facial phenotype was present in patients with mutations in 
GLIS3 and whether there was a recognisable facial gestalt. 
 
MATERIALS AND METHODS 
 
The study was conducted in accordance with the Declaration of Helsinki principles 
with informed parental consent given on behalf of children. Clinical information was provided 
by the referring clinicians, from clinical notes and subsequently using a questionnaire 
circulated to referring clinicians to gain further information. Consent was received from 
parents to publish photographs of facial features resulting from mutations in GLIS3.  
 
Genetic analysis 
 
GLIS3 gene mutations were identified by PCR amplification (primer sequences 
available on request) and sequence analysis of exons 1±11 by comparison with the reference 
sequence NM_001042413. Exon 1 is non-FRGLQJWKH¶875DQGWKHVWDUWFRGRQLVORFDWHG
within exon 2. The effect of coding variants on the protein was investigated in silico using the 
bioinformatic tool ALAMUT (Interactive Biosoftware, Rouen, France). When failure of PCR 
amplification occurred, suggesting a homozygous deletion, parental samples were 
investigated by real-time quantitative PCR on an ABI 7900 (TaqMan assay with SYBR Green 
detection) and the copy number of exons 1±11 was determined by the 2-ǻǻ&W method. 
Patient 4 was analysed for all the known neonatal diabetes genes using a targeted next 
generation assay [Ellard et al., 2013]. Mutations identified by this assay were confirmed by 
Sanger sequencing. 
 
RESULTS 
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Table 1 describes the nucleotide and predicted protein changes of the GLIS3 
mutations identified in the patients studied. Table 2 describes the clinical features in the 
cohort reported here and the homozygous GLIS3 mutation results (6 with deletions and one 
with a homozygous missense mutation). Patients 2 and 3 are siblings aged 7 and 2.4 years 
respectively. A consistent facial phenotype is seen at a younger age in patients i.e. bilateral 
low-set ears, depressed nasal bridge with upturned nose, prominent eyes, long philtrum with 
a thin vermilion border of the upper lip (Figure 1). With age, rather than being attenuated as 
described in previously published literature [Senee et al., 2006], it appears to evolve into a 
more recognisable facial gestalt consisting of bilateral low-set ears, depressed nasal bridge 
with overhanging columella, elongated, upslanted palpebral fissures, persistent long philtrum 
with a thin vermilion border of the upper lip. This demonstrates the consistent facial 
phenotype in patients with GLIS3 mutations. The oldest patient in this series is 7-years of age 
and appears to have a distinct facial gestalt (Patient 1). 
 
Figure 2 demonstrates the progression of the facial phenotype with age in the same 
patient (Patient 5) from newborn, age 2 up to 4.3 years whilst Figure 3 demonstrates the 
striking resemblance of patients in this series to the images previously published by Senee et 
al., 2006 (reproduced with relevant permission from Nature Publishing Group).  
 
DISCUSSION 
 
GLIS3 is a member of the GLI-similar zinc finger protein family encoding for a nuclear 
protein that maps to chromosome 9p24.3-p23 (OMIM *610192) [Kim et al., 2003]. Mutations 
in GLIS3 have been reported in association with Neonatal diabetes mellitus and 
hypothyroidism syndrome (NDH syndrome - OMIM #610199). GLIS3 is expressed in early 
embryogenesis and plays a critical role as both a repressor and activator of transcription by 
interacting with a specific nucleotide sequence, known as the Gli response element (GLI-RE) 
in the promoter region of target genes [Kim et al., 2003; Beak et al., 2008]. Glis proteins 
contain a DNA binding domain consisting of five C2H2-type zinc finger motifs that are critical 
for nuclear localisation. Two major GLIS3 transcripts from the 11 exon gene have previously 
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been described ± 7.5 kb and smaller (0.8±2.0 kb); the 7.5-kb transcript is strongly expressed 
in pancreas, thyroid and kidney with smaller transcripts predominantly expressed in liver, 
kidney, eye, heart and skeletal muscle [Senee et al., 2006]. The cardinal feature of mutations 
in GLIS3 is the concomitant presentation of neonatal diabetes and congenital hypothyroidism 
although recently a patient with a compound heterozygous mutation in GLIS3 who did not 
develop hypothyroidism was reported [Dimitri et al., 2015].  
 
Neonatal diabetes is likely to result from the disrupted interaction of GLIS3 with key 
regulatory genes in pancreatic embryogenesis including ONECUT1 and NEUROGENIN3 
(NEUROG3) [Kim et al., 2012; Poll et al., 2006; Kang et al., 2009]. GLIS3 expression persists 
beyond the embryonic period promoting beta cell proliferation and regulating insulin gene 
expression through binding to GLI-RE on the INS gene [Yang et al., 2013]. The proposed 
mechanism by which biallelic pathogenic variants in GLIS3 causes a multi-system phenotype 
has been reported elsewhere [Senee et al., 2006; Dimitri et al., 2015].  
 
GLIS3 is expressed during embryonic face development [Kim et al., 2003], which may 
help in part to explain the dysmorphic facial features observed in these patients. In studies of 
mouse embryos, whole mount in situ hybridisation from stage e6.5 to e14.5 was used to 
determine the temporal and spatial patterns of GLIS3 expression during development. Facial 
expression of GLIS3 was greatly increased form e11.5 and e12.5, and expression was 
mesenchymal in origin. GLIS3 is also expressed in a dynamic pattern during eye 
development and at e8.75, GLIS3 transcripts were evident in the region of the otic vesicles. 
Given the commonality of GLIS3 expression with bone morphogenic proteins (BMPs) and 
RWKHUPHPEHUVRI WKH7*)ȕVXSHUIDPLO\ Lnteractions between BMPs and GLIS3 have been 
speculatively proposed as a possible underlying mechanism that is important for facial 
development. However, beyond this, there is no clear genetic interaction to explain the 
common facial dysmorphology observed in patients with mutations in GLIS3.  
 
Table 2 provides clinical features in patients reported in this series demonstrating the 
multi-system phenotype associated with mutations in GLIS3. Patients 1-5 presented with mild 
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developmental delay with age at walking ranging between 13-21 months of age and first word 
between 15-18 months of age. Patients 6-7 did not have any evidence of developmental 
delay. As evident from the patient images, all the patients in this series appear to have a 
similar facial gestalt with bilateral low-set ears, prominent eyes with upslanted palpebral 
fissures, depressed nasal bridge, long philtrum and thin vermilion border of the upper lip 
(Figure 1). The facial features become more evident and established with advancing age 
(Figure 2). The patients reported in this series appear to have similar facial features as the 
patients reported by Senee et al., 2006. The two siblings from the third family in the reported 
series- NDH3-3 and NDH3-4, at age 6-months and 2 years respectively were said to have 
characteristic facial features (Figure 3). In our cohort, Patient 7 in particular appears to have a 
very similar facial dysmorphology to the patient at 6-months of age (NDH3-3- Senee et al., 
2006) whilst Patient 1 in our series appears to share the same facial gestalt as the patient at 
2-years of age (NDH3-4- Senee et al., 2006). Two of the patients in this series, patient 4 and 
6, have mutations which affect only the GLIS3 gene (an interstitial deletion and a missense 
mutation), supporting the hypothesis that the facial features observed result from the GLIS3 
defect alone and not from the deletion of contiguous genes. The patients not included in this 
series (including a 36-year old adult) that were previously reported have the same facial 
dysmorphism as described above but as we have been unable to obtain written consent from 
patient and their families, we have been unable to include this in this report [Dimitri et al., 
2015]. 
 
In combination with the other features in NDH, it is important to recognise the facial 
gestalt in this group of patients in order to direct targeted genetic testing and provide 
genotype-phenotype correlation. This is particularly important as making an early diagnosis 
and instituting therapeutic intervention is crucial given the course of disease pathology in 
NDH syndrome. In conclusion, we report a common and emerging facial gestalt in patients 
with GLIS3 mutations that are not attenuated with age. Further case reports of this nature are 
crucial in elaborating the common facial phenotype in NDH and attributing a consistent facial 
phenotype to this genetic condition. 
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FIGURE LEGENDS: 
 
Figure 1: Patients 1-7 demonstrating common facial dysmorphism including bilateral low-set 
ears, depressed nasal bridge with upturned nose, long philtrum with thin vermilion border of 
the upper lip; with advancing age the facial phenotype becomes more distinctive with up-
slanting, elongated palpebral fissures, long philtrum with thin vermilion border of the upper lip 
and more rounded appearance to the face.  
 
Figure 2: Patient 5 showing evolving facial phenotype from newborn to age 4.3 years. 
 
Figure 3: Images of Patient 7 and 1 in comparison to facial dysmorphism of patients 
published by Senee et al., 2006 [NDH3-3 aged 6-months and NDH3-4 aged 2 years; 
reproduced with relevant permission from Nature Publishing Group]. 
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TABLES: 
 
Table 1: Mutations and nucleotide changes associated relating to mutations in GLIS3 
Patient 
number 
Exon 
 
Mutation 
 
Nucleotide change 
 
In silico 
prediction 
Current 
age 
(years) 
1 1-2 exons 1-2 
del/exons 1-2 
del 
c.-?_388+?del/c.-
?_388+?del 
Pathogenic 7.1 
 
2 
1-4 exons 1-4 
del/exons 1-4 
del 
c.-?_1710+?del/c.-
?_1710+?del 
Pathogenic 7.0 
 
3 
1-4 exons 1-4 
del/exons 1-4 
del 
c.-?_1710+?del/c.-
?_1710+?del 
Pathogenic 2.4 
 
4 
5-9 exons 5-9 
del/exons 5-9 
del 
c.1711-
?_2473+?del/c.1711-
?_2473+?del 
Pathogenic 4 
 
5 
9-11 exons 9-11 
del/exons 9-11 
del 
c.2298-
?_2657+?del/c.2298-
?_2657+?del 
Pathogenic Died at 6 
years  
 
6 
4 p.His561Tyr/p.H
is561Tyr 
c.1681C>T/c.1681C>T Pathogenic 5.3 
 
7 
1-2 exons 1-2 
del/exons 1-2 
del 
c.-?_388+?del/c.-
?_388+?del 
Pathogenic 5 
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Table 2: Clinical features presenting in patients with GLIS3 mutations 
Patient 
number 
Current 
age 
(years) 
Birth 
weight 
(g) 
IUGR* Gestation 
(weeks) 
Ethnicity Gender Consanguineous PND 
Onset~ 
(days) 
Congenital 
Hypothyroidism 
Liver 
disease 
Kidney 
disease 
Exocrine 
pancreatic 
disease 
Congenital 
Glaucoma 
Skeletal 
Disease 
Developmental 
delay 
Facial 
dysmorphism 
Other features 
1 7.1 1170 Yes 35 Bangladeshi Female Yes 3 Yes Yes Yes Yes No Osteopenia, 
fractured ribs, 
scoliosis 
Yes, mild Yes No 
2 7.0 1430 Yes 35 Caucasian Male No 4 Yes Yes Yes Yes No No Yes, mild Yes BSNHL^ 
PDA 
Pancreatic cyst 
3 2.4 2020 Yes 38 Caucasian Male No 2 Yes Yes Yes Yes No No Yes, mild Yes Pancreatic & 
Splenic cyst 
BSNHL 
4 4 1750 Yes 34 Arab Female Yes 2 Yes Yes Yes No No No 
 
Yes, mild Yes No 
5 Died at 
6 years  
1530 Yes 37 African-
American 
Female Unknown 7 Yes Yes Yes No Yes Sagittal 
craniosynostosis 
Yes, mild Yes No 
6 5.3 973 Yes 31 Kurdish Male Yes 31 Yes Yes Yes No Yes No No Yes PDA$ 
7 5 1730 Yes 39 Arab Male Yes 19 Yes No 
 
Yes No Yes No No Yes Ostium 
secundum 
ASD# 
 
*Birth weight < 10th centile for gestational age; ~ND ± Permanent neonatal diabetes; ^BSNHL- Bilateral sensori-neural hearing loss; $PDA- Patent ductus arteriosus; #ASD ± Atrial Septal Defect 
 
 
